The documented U.S. regulatory footprint for Risu Medical Technology Co., Ltd. is a single premarket notification, K262349, received by FDA on July 10, 2026, and decided October 27, 2026 as Substantially Equivalent. The applicant name on the FDA record is the company itself; the correspondence address on the decision letter runs through a named Shanghai consultant. The company's own website describes a broader laser product line, which is separate from what the FDA record covers. [1][2][3]
The K262349 filing and its scope
K262349 covers a diode laser device listed under five model designations: DT25-BI, DT212-BI, DT213-BI, DT214-BI and DT215-BI. FDA classified it as a Powered Laser Surgical Instrument, class 2, product code GEX, under 21 CFR 878.4810, with the advisory committee recorded as General, Plastic Surgery. The clearance type is Traditional, the third-party review flag is N, and the statement or summary field reads Summary. [1][6][9]
The decision letter is addressed to Risu Medical Technology Co., Ltd. care of Owen He, Consulant Microkn Medical Technology Service (Shanghai) Co., Ltd., at an address in Jing'An District, Shanghai. That is a correspondence address on the letter, not a statement of corporate headquarters. The letter restates the trade name, the regulation number and the regulation name for the device. [2]
The decision letter describes the comparison basis for the submission: the proposed device was compared with legally marketed predicate devices, with a general comparison against K240747 for the 980 nm and 1470 nm wavelengths and general comparisons against K193656 and K210367 for the 650 nm wavelength. The letter's comparison table lists product code GEX for both the proposed device and predicate device 1. [2]
Where the record sits in the wider collection
The supplied filing collection, as of November 20, 2026, contains one linked record, and that record is on the 510(k) pathway with a decision of SESE. The explicitly smaller record sample also contains one entry, K262349, with the same decision. These are counts of the supplied filings at that date, not measures of company sales, total portfolio or safety performance. [1][6]
A separate openFDA query covering decision dates from October 15 to November 11, 2026 returned 192 results in total, and a query covering October 26 to November 16, 2026 returned 95 results. K262349 appears in the latter result set with the same device name, applicant, product code, decision description and dates. Neither figure describes Risu's own output. [7][8]
Products described by the company
Risu's own website presents itself as a medical laser manufacturer and ODM/OEM solutions provider and lists a product range that includes the EpiLase diode laser device, the RisuPico picosecond laser device, the LuminaQ Q-switch laser device, a dual-wavelength diode laser device and a handheld diode laser device. The site's product categories also name picosecond, Q-switched Nd:YAG, 980 nm plus 1470 nm diode and diode laser hair removal lines. These are company-published descriptions; the FDA record documents only the diode laser device under K262349. [3][5]
The company's about page states that Risu Med works across upstream components such as chips, crystals and coatings, midstream component packaging including optical devices, fiber optic devices and chip packaging modules, and functional units including semiconductor lasers, solid-state lasers and electronic control components. The same page shows CE certification graphics without accompanying certificate details in the public information. [4]
Corporate details as published
The company website lists a headquarters address on the 2nd Floor, Building 11, Phase III, Western Cloud Valley, Xixian New Area, Xi'an, Shaanxi Province, and a Beijing operations center at Bodian Innovation Park in the Beijing Economic and Technological Development Area. The same page gives a telephone number, an email address and social media links. The FDA filing record separately lists a Xian city and postal code 712000 with contact Fuyan Yang. [1][3]
The website also publishes facility figures of 3000+ square meters of factory area, laboratory areas listed at 700+ and 1000+ square meters, and 300+ R&D engineers. These figures come from the company's own site and are not corroborated by the FDA record. No parent company, ownership structure or brand relationship beyond the Risu name is verified in the public documents. [3][4]

